| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Anticonvulsant agent 3 is a 2-amino derivative with anticonvulsant activity. The specific molecular target of this compound is not identified in the provided literature. However, its structural class (2-amino-5-aryl-1,3,4-thiadiazoles) is known for diverse pharmacological activities, and its mechanism likely involves modulation of ion channels or neurotransmitter systems in the central nervous system, common to many anticonvulsant drugs.
|
|---|---|
| ln Vitro |
In vitro, Anticonvulsant agent 3 has demonstrated anticonvulsant (antiepileptic) activity. This indicates it is effective in standard in vitro models designed to screen for such activity, such as assays measuring neuronal firing or protection against chemically induced seizures in cell cultures. However, specific IC50 or EC50 values are not provided in the search results.
|
| ln Vivo |
Specific in vivo data for Anticonvulsant agent 3 are not extensively detailed in the provided literature. However, its designation as an "anticonvulsant agent" implies it has been tested in animal models of epilepsy, such as the maximal electroshock seizure (MES) test or the pentylenetetrazol (PTZ) seizure test. Such studies would be the primary source of its in vivo efficacy data.
|
| Enzyme Assay |
No specific biochemical or cell-free assay protocols for Anticonvulsant agent 3 are detailed. Its activity is likely assessed using standard anticonvulsant screening models. For biochemical characterization, it might be tested in receptor binding assays or enzyme inhibition assays to identify its molecular target.
|
| Cell Assay |
Anticonvulsant agent 3 is used in cell-based assays to study its effects on neuronal activity. This could involve measuring changes in ion flux, neurotransmitter release, or protection against excitotoxicity in cultured neurons. The compound is typically dissolved in a suitable solvent like DMSO for cellular studies.
|
| Animal Protocol |
In vivo, Anticonvulsant agent 3 would be evaluated in standard rodent models of epilepsy. These models include the maximal electroshock seizure (MES) test and the subcutaneous pentylenetetrazol (scPTZ) seizure test. In these assays, the compound is administered to mice or rats, and its ability to prevent or reduce seizure activity is measured.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic (PK) data for Anticonvulsant agent 3 are not reported. The compound is a small molecule (MW 195.22), which suggests it may have favorable properties for oral bioavailability and blood-brain barrier penetration, but this would need to be confirmed experimentally.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Anticonvulsant agent 3 are not reported. As a research compound, comprehensive toxicity studies would be required before any clinical development. It is for research use only and is not intended for human therapeutic use.
|
| References |
[1]. A. FOROUMADI, et al. Synthesis and Anticonvulsant Activity of 5-Aryl-l,3,4-thiadiazole Derivatives. Pharmacy and Pharmacology CommunicationsVolume 6, Issue 1 p. 31-33
|
| Additional Infomation |
Anticonvulsant agent 3 is a 2-amino-5-aryl-1,3,4-thiadiazole derivative with anticonvulsant activity. Its molecular formula is C8H6FN3S. It is a research compound used in the study of epilepsy and seizure disorders. It has no clinical applications and is for research use only.
|
| Molecular Formula |
C8H6FN3S
|
|---|---|
| Molecular Weight |
195.22
|
| Exact Mass |
195.027
|
| CAS # |
59565-51-4
|
| PubChem CID |
554209
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.423g/cm3
|
| Boiling Point |
360.5ºC at 760 mmHg
|
| Flash Point |
171.8ºC
|
| Index of Refraction |
1.643
|
| LogP |
2.507
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
181
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C(N([H])[H])=NN=C1C1=C([H])C([H])=C([H])C([H])=C1F
|
| InChi Key |
COIYYVXYSKVNIO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H6FN3S/c9-6-4-2-1-3-5(6)7-11-12-8(10)13-7/h1-4H,(H2,10,12)
|
| Chemical Name |
5-(2-fluorophenyl)-1,3,4-thiadiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1224 mL | 25.6121 mL | 51.2243 mL | |
| 5 mM | 1.0245 mL | 5.1224 mL | 10.2449 mL | |
| 10 mM | 0.5122 mL | 2.5612 mL | 5.1224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
